Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Entresto
Pharma
Novartis gears up for key expansions of 3 cancer drugs
Pluvicto, Ksiqali and Scemblix have key new indications lined up for them in earlier treatment settings. But they all slightly disappointed in Q1.
Angus Liu
Apr 23, 2024 3:37pm
Novartis puts Kisqali's peak sales potential at above $7B
Nov 28, 2023 10:48am
After Entresto makes CMS list, Novartis files suit vs. IRA
Sep 5, 2023 11:17am
CMS names 10 drugs up for first price negotiations under IRA
Aug 29, 2023 9:27am
Marketing regulator sounds alarm over Novartis' Entresto podcast
Aug 14, 2023 10:54am
Novartis to buy back $15B in shares despite Entresto setback
Jul 18, 2023 11:05am